Guyana vs Morocco: Average cost of multi drug-resistant tuberculosis treatment
Guyana
2,586 constant 2022 US$
in 2024
Morocco
2,000 constant 2022 US$
in 2024
Guyana rank
19th
Morocco rank
22nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Guyana
- Morocco
How they compare
Guyana currently reports 2,586 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco, a difference of 586 constant 2022 US$.
That makes Guyana's figure about 1.3 times Morocco's.
The two have swapped places 4 times across 7 shared years of data; in 2017 it was Guyana ahead.
Guyana ranks 19th and Morocco ranks 22nd of 92 countries.
Guyana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guyana | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,450 constant 2022 US$ | 1,335 constant 2022 US$ | 115.5 constant 2022 US$ | Guyana |
| 2020s | 1,778 constant 2022 US$ | 1,644 constant 2022 US$ | 133.4 constant 2022 US$ | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guyana or Morocco?
- Guyana, at 2,586 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guyana and Morocco?
- 586 constant 2022 US$, with Guyana ahead.
- How many years of comparable data are there for Guyana and Morocco?
- 7 years are reported by both, from 2017 to 2024.
- How do Guyana and Morocco rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guyana ranks 19th and Morocco ranks 22nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.